Since the first publication on the activity of the carboplatin–vincristine combination in paediatric low-grade glioma in 1993,1 chemotherapy has become the mainstay of treatment for this condition, particularly in young children (aged 0–10 years). However, 5-year event-free survival in the non-neurofibromatosis type 1 (NF1) population is in the range of 40% and most patients require several lines of treatment.2 Patients with NF1 have a longer event-free survival than those without NF1, ranging between 65% and 85%.
Read Full Article
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου